Transaction overview
On February 27, 2026, a group of funds and affiliated entities including Innovex Co-Invest Fund, Intervale Capital Fund and related vehicles sold a combined 6,629,591 shares of Innovex International, Inc. (NASDAQ: INVX). The disposals were carried out at $24.5913 per share, producing gross proceeds of approximately $162.6 million.
Breakdown of sellers
The sales were executed by multiple named entities, with the following reported quantities:
- Amberjack Capital Fund II, L.P. - 4,902,244 shares
- Innovex Co-Invest Fund II, L.P. - 1,144,635 shares
- Innovex Co-Invest Fund, L.P. - 271,279 shares
- Intervale Capital Fund II, L.P. - 234,009 shares
- Intervale Capital Fund III, L.P. - 60,217 shares
- Intervale Capital Fund II-A, L.P. - 116 shares
Reports indicate that, despite the sales, these entities continue to hold meaningful positions in Innovex International, Inc. Jason Turowsky, listed as Partner, signed on behalf of multiple entities connected to the transactions.
Market reaction and valuation notes
Following the transactions, INVX shares rose to $26.35. The stock has exhibited notable momentum, trading up 53% over the last six months, according to InvestingPro data. The same platform's analysis indicates the shares may still trade below their Fair Value and references a Pro Research Report for further detail.
Company financials and related offering
In separate corporate disclosures, Innovex International Inc. reported fourth-quarter financial results showing mixed outcomes. The company posted adjusted earnings per share of $0.20, which fell short of the analyst consensus of $0.29. Revenue, however, came in at $273.6 million versus an estimated $239.47 million. That revenue figure represented a 9% increase from the comparable quarter a year earlier and a 14% increase sequentially from the prior quarter.
Also disclosed were plans by certain affiliates of Amberjack Capital Partners, L.P. to sell 5.75 million shares of Innovex common stock in a public offering. The selling stockholders granted the underwriters a 30-day option to buy up to an additional 862,500 shares. The company stated it will not sell any shares in that offering and will not receive proceeds from the sale.
Context and next steps
The coordinated dispositions, the public offering by selling stockholders and the firm’s mixed fourth-quarter results together form the immediate factual picture described in filings and market data. For investors or analysts seeking further valuation context, the referenced Pro Research Report is noted as an available source of deeper analysis.